Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamibarotene for Alzheimer's Disease
jRCT2090220288Completed
- Sponsor
- Fumihiko Yasuno
- Start
- Apr 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Alzheimer's disease (AD) comparing Tamibarotene 4 mg QD with Placebo QD (2 arms). Primary endpoint: Cognitive function and clinical outcomes. Started Apr 2017; status: completed.
02
Drugs
tamibarotene
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2090220288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2090220288.